Abstract
Acute lymphoblastic leukemia requires around 18 months of daily oral chemotherapy called 6-mercaptopurine (6-MP) for treatment. Previous research has included a broad age range and shows adolescent/young adult (AYA) age and minoritized race/ethnicity are associated with lower adherence. Few studies have evaluated how these intersecting identities impact adherence. In a retrospective analysis of an AYA sample, we evaluated the relationships between race/ethnicity, area deprivation index (ADI), and insurance with electronically monitored 6-MP adherence. Results showed minoritized race/ethnicity and ADI correlated with adherence. Findings highlight the need for equitable interventions that enhance adherence and improve outcomes among AYAs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
